Glaukos Corporation (GKOS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Glaukos Corporation (GKOS:NYSE), powered by AI.

Current Price
$112.77
P/E Ratio
-40.6
Market Cap
5.9B
Sector
Healthcare
What is the Glaukos Corporation stock price forecast?

Glaukos Corporation is currently trading at $112.77. View real-time AI analysis on Alpha Lenz.

What is Glaukos Corporation insider trading activity?

View the latest insider trading data for Glaukos Corporation on Alpha Lenz.

What is Glaukos Corporation's P/E ratio?

Glaukos Corporation's P/E ratio is -40.6.

Glaukos Corporation

$112.77
NYSEGKOS
Ask about Glaukos Corporation's future dividend policy...
Alpha Chat Insight

Glaukos Corporation trades at a P/E of -40.6 (undervalued) with modest ROE of -23.8%.

Ask for details

Company Overview

Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.

CEOMr. Thomas William Burns
SectorHealthcare
IndustryMedical Devices
Employees995

Company Statistics

(FY 2024)

Profile

Market Cap$5.95B
Revenue$383.48M
Shares Out0.00
Employees995

Margins

Gross75.48%
EBITDA-21.23%
Operating-28.20%
Pre-Tax-37.97%
Net-38.17%

Valuation

P/E-40.64
P/B7.76
EV/Sales15.51
EV/EBITDA-72.26
P/FCF-87.98

Growth (CAGR)

Rev 3Yr9.26%
Rev 5Yr10.10%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-15.29%
ROE-23.83%
ROIC-14.16%

Financial Health

Cash & Cash Equivalents$169.63M
Net Debt$38.20M
Debt/Equity27.10%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Glaukos Corporation (Healthcare) Stock Forecast & Analysis $112.77 | Alpha Lenz